Clinical Trials Browser

INDUSTRY × Colorectal Neoplasms × balstilimab × Clear all

NCT05205330 2025-10-29

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Phase 1/2 Active not recruiting

107 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms